中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

U.S. FDA Fast Track Designation Granted for Envafolimab in Soft Tissue Sarcoma Subtypes

On September 14，Envafolimab, the worlds first subcutaneously PD-L1 inhibitor has received Fast Track designation granted by the U.S. FDA to be used ...

2022-09-16
Simcere Ranked Among Top 100 China Pharma Innovation Enterprise 2022 released by Healthcare Executive

Simcere ranked among first tier of TOP 100 China Pharma Innovation Enterprise，as well as TOP10 Innovative R&D Force Among Listed China Pharma，char...

2022-09-16
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue

August 31, 2022, Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As of June 30, Simcere rec...

2022-09-05
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group

September 1st 2022，Simcere Pharmaceutical Group announces today the appointment of Tamas Oravecz, Ph.D. as Senior Vice President, Chief Scientif...

2022-09-01
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.